It is biology doing what biology does, which is defending a set point through a tangle of overlapping appetite signals
GLP-1 Drugs and Eating Disorders: A Hidden Risk in the Weight Loss Revolution By Donnisa Edmonds, C2ST Intern, University of Chicago In 2021, the FDA announced that they had approved Wegovy, a GLP-1 receptor agonist, as a treatment for chronic weight management
26,43,44 The enzymes UGT (glucouronidation), SULT, CYP 450, GST, N -deacetylase (deacetylation), NAT2 (deacetylation), and fatty acid amide hydrolase are involved in APAP metabolism and have been shown to be related to both hepatic and nephrotoxic effects of the analgesic medication
Related Reads 1
Cannabis may counteract Ozempic's appetite-suppressing effects and cause unpredictable fluctuations in blood glucose levels
There is no caffeine, no synephrine, no beta-phenylethylamine, and no other central nervous system stimulants